Shots:

• The P-III ASCEND program includes 5 studies i.e ASCEND-ND- D- ID- NHQ & TD studies evaluating efficacy & safety of daprodustat vs ESA in ~8-000 patients with anemia due to CKD for ~ 3.75yrs.
• The program met its 1EPs in 5 studies i.e improvement in Hgb levels in untreated patients and maintaining Hgb levels in patients treated with ESA. Therapy was generally well-tolerated in both non-dialysis & dialysis patients- AEs were similar b/w treatment groups
• The co-primary EPs of ASCEND-ND & ASCEND-D studies in non-dialysis and dialysis patients showed that the therapy was non-inferior compared to an ESA in the risk of MACE. The therapy is currently approved as Duvroq for renal anemia in Japan

  Ref: GSK | Image: GSK